Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP0057 + Olaparib in Advanced Ovarian Cancer
NCT04669002Phase 2Completed
- Sponsor
- Ellipses Pharma
- Start
- Dec 2020
- Primary completion
- Feb 2023
- Modality
- Polymer-based Nanoparticles
- Countries
- 3
01
Overview
A Phase 2 trial of CRLX101 in ovarian cancer, sponsored by Ellipses Pharma. Started Dec 2020; status: completed.
02
Drugs
CRLX101
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04669002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04669002.